Poised to launch, the product will be sold in 1 mL single-dose vials as well as in 5 mL and 10 mL multiple dose vials.
|
|
| [12-December-2017] |
|
BRIDGEWATER, N.J., Dec. 12, 2017 /PRNewswire/ -- Amneal Biosciences received approval yesterday for its Triamcinolone Acetonide Injectable Suspension, USP in 40 mg/mL dosage strength. Poised to launch, the product will be sold in 1 mL single-dose vials as well as in 5 mL and 10 mL multiple dose vials. With just the Kenalog®-40 brand currently on the market, Amneal's triamcinolone acetonide will be the only AP-rated generic equivalent injectable suspension available. "This important launch demonstrates the depth of our ability to successfully develop and manufacture complex products in our state-of-the-art manufacturing facilities," notes Chirag Patel, Co-CEO and co-Chairman for Amneal Pharmaceuticals. "We are very pleased to launch the only generic injectable of triamcinolone, bringing this affordable medication to patients and healthcare providers," says Amneal Biosciences President Charles Lucarelli. "We will continue to focus on expanding our portfolio to provide quality generic injectables to our healthcare system." Annual U.S. sales of Kenalog-40 injection were $146 million according to October 2017 IQVIA™ market data. Triamcinolone acetonide injectable suspension will be available direct and through wholesalers and distributors. About Amneal Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and fastest growing generic pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,100 employees in its operations in North America, Asia, and Europe, working together to bring high-quality, affordable medicines to patients worldwide. All trademarks listed in this release are property of their respective owners. CONTACTS: Sales: Business Development: Media : SOURCE Amneal Biosciences |
